Cantor Fitzgerald initiated coverage of Crispr Therapeutics with an Overweight rating and $72 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Surges 16% as Cantor Fitzgerald Assigns $72 PT
- CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
- Vertex Pharmaceuticals, Crispr Therapeutics complete rolling BLAs to FDA
- Bluebird Bio reaction to lovo-cel BLA delay ‘overdone,’ says Raymond James
- Crispr Therapeutics announces departure of board member